Top 10 retina articles of 2017

Retina news in 2017 included anti-VEGF developments and clinical trial updates for a number of new drugs for a variety of indications.

Here are the top 10 most read retina articles on Healio.com/OSN in 2017:

 

1. Brolucizumab shows noninferiority to aflibercept for treatment of AMD

Two phase 2 studies comparing brolucizumab vs. aflibercept for the treatment of neovascular age-related macular degeneration showed comparable efficacy results at 40 weeks of follow-up. Read more.

 

2. Lampalizumab reduces geographic atrophy lesion progression

Monthly lampalizumab, a potential therapy for patients with geographic atrophy secondary to age-related macular degeneration, reduced lesion area progression by 20% compared to a sham control, according to results of the MAHALO study. Read more.

 

3. Staring at eclipse may cause solar retinopathy

Remember when you were a kid and you used a magnifying glass to concentrate the sun’s energy to burn paper? Solar retinopathy is like that except it is the fovea that is getting burned. Read more.

 

4. YAG laser vitreolysis improves symptomatic vitreous floaters

YAG laser vitreolysis was associated with a better improvement in vitreous floater symptoms than a sham procedure, according to study findings. Read more.

 

5. Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials

RTH258 for wet age-related macular degeneration met its primary and key secondary endpoints in two phase 3 studies. Read more.

 

6. Intravitreal implant with brimonidine reduced GA lesion growth in phase 2 study

A brimonidine drug delivery system was well tolerated and reduced geographic atrophy lesion growth, nearing statistical significance at year 2 with a higher dose, based on a phase 2, multicenter, double-masked study presented at the Association for Research in Vision and Ophthalmology annual meeting. Read more.

 

7. Protocol U: No overall difference between single, combined treatments

No overall difference was found in mean visual acuity gains in patients treated with Lucentis alone or with Lucentis plus dexamethasone, according to a speaker at the American Academy of Ophthalmology meeting. Read more.

 

8. Genentech completes enrollment in two phase 3 lampalizumab studies

Patient enrollment has been completed in two phase 3 trials of lampalizumab, which is being investigated for reducing the progression of geographic atrophy lesions secondary to age-related macular degeneration. Read more.

 

9. Good results seen in phase 3 trial of tocilizumab in giant cell arteritis

Tocilizumab was shown to have a statistically significant inhibiting effect on IL-6, which is known to be elevated in patients with giant cell arteritis, according to the results of a phase 3 study presented at the North American Neuro-Ophthalmology Society annual meeting. Read more.

 

10. FDA grants NDA for intravitreal sirolimus for non-infectious uveitis of posterior segment

The FDA has accepted a new drug application for intravitreal sirolimus for the treatment of non-infectious uveitis of the posterior segment. Read more.

 

 

Retina news in 2017 included anti-VEGF developments and clinical trial updates for a number of new drugs for a variety of indications.

Here are the top 10 most read retina articles on Healio.com/OSN in 2017:

 

1. Brolucizumab shows noninferiority to aflibercept for treatment of AMD

Two phase 2 studies comparing brolucizumab vs. aflibercept for the treatment of neovascular age-related macular degeneration showed comparable efficacy results at 40 weeks of follow-up. Read more.

 

2. Lampalizumab reduces geographic atrophy lesion progression

Monthly lampalizumab, a potential therapy for patients with geographic atrophy secondary to age-related macular degeneration, reduced lesion area progression by 20% compared to a sham control, according to results of the MAHALO study. Read more.

 

3. Staring at eclipse may cause solar retinopathy

Remember when you were a kid and you used a magnifying glass to concentrate the sun’s energy to burn paper? Solar retinopathy is like that except it is the fovea that is getting burned. Read more.

 

4. YAG laser vitreolysis improves symptomatic vitreous floaters

YAG laser vitreolysis was associated with a better improvement in vitreous floater symptoms than a sham procedure, according to study findings. Read more.

 

5. Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials

RTH258 for wet age-related macular degeneration met its primary and key secondary endpoints in two phase 3 studies. Read more.

 

6. Intravitreal implant with brimonidine reduced GA lesion growth in phase 2 study

A brimonidine drug delivery system was well tolerated and reduced geographic atrophy lesion growth, nearing statistical significance at year 2 with a higher dose, based on a phase 2, multicenter, double-masked study presented at the Association for Research in Vision and Ophthalmology annual meeting. Read more.

 

7. Protocol U: No overall difference between single, combined treatments

No overall difference was found in mean visual acuity gains in patients treated with Lucentis alone or with Lucentis plus dexamethasone, according to a speaker at the American Academy of Ophthalmology meeting. Read more.

 

8. Genentech completes enrollment in two phase 3 lampalizumab studies

Patient enrollment has been completed in two phase 3 trials of lampalizumab, which is being investigated for reducing the progression of geographic atrophy lesions secondary to age-related macular degeneration. Read more.

 

9. Good results seen in phase 3 trial of tocilizumab in giant cell arteritis

Tocilizumab was shown to have a statistically significant inhibiting effect on IL-6, which is known to be elevated in patients with giant cell arteritis, according to the results of a phase 3 study presented at the North American Neuro-Ophthalmology Society annual meeting. Read more.

 

10. FDA grants NDA for intravitreal sirolimus for non-infectious uveitis of posterior segment

The FDA has accepted a new drug application for intravitreal sirolimus for the treatment of non-infectious uveitis of the posterior segment. Read more.